Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 +/- Paclitaxel in Recurrent Gyn Cancers
NCT03395080Phase 2Completed
- Sponsor
- Leap Therapeutics, Inc.
- Start
- Mar 2018
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sirexatamab in endometrial cancer (EC), epithelial ovarian cancer (EOC), carcinosarcoma, sponsored by Leap Therapeutics, Inc.. Started Mar 2018; status: completed.
02
Drugs
sirexatamab
03
Conditions
endometrial cancer (EC)epithelial ovarian cancer (EOC)carcinosarcoma
Beyond the preview
Go deeper on NCT03395080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395080.